1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

pancreatic cancer cell

" in MedChemExpress (MCE) Product Catalog:

258

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

9

Peptides

17

Inhibitory Antibodies

29

Natural
Products

8

Isotope-Labeled Compounds

4

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160715

    Toll-like Receptor (TLR) Cancer
    BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) .
    BNT411
  • HY-143657

    Myosin Ferlin Family MMP Cancer
    Myoferlin inhibitor 1 is a compound that exhibits reversible, concentration-dependent binding to the myoferlin MYOF-C2D protein, with a KD of 0.094 μM. Myoferlin inhibitor 1 shows potent anti-invasion and anti-migration activities against different pancreatic cancer cells. Myoferlin inhibitor 1 inhibits pancreatic cancer metastasis through reversing mesenchymal transition (EMT), inhibiting the secretions of MMP1 and MMP2 and blocking the receptor tyrosine kinases. Myoferlin inhibitor 1 displays effective antimetastatic activities in pancreatic cancer in vitro and in vivo. Myoferlin inhibitor 1 can be used in research on preventing pancreatic cancer metastasis .
    Myoferlin inhibitor 1
  • HY-178521

    Cadherin Cancer
    BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC) .
    BAS00602705
  • HY-175230

    Lactate Dehydrogenase Apoptosis Cancer
    ZG-2492 is an orally active LDHA inhibitor with an IC50 of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .
    ZG-2492
  • HY-P991378

    Transmembrane Glycoprotein Cancer
    MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
    MORAb-066
  • HY-P991318

    Mucin Cancer
    AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
    AR20.5
  • HY-149076

    Drug Derivative Cancer
    hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.
    hGAPDH-IN-1
  • HY-150970

    Pyroptosis Cancer
    ICy-OH, an iodinated photosensitizer, is an effective anticancer agent. ICy-OH can be used not only for deep tissue imaging (λex=640 nm,λem=690-740 nm) but also to selectively induce cell death in pancreatic cancer cells via cell pyroptosis pathway .
    ICy-OH
  • HY-169741

    Discoidin Domain Receptor Cancer
    DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .
    DDR1-IN-10
  • HY-149607

    SHP2 Cancer
    SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .
    SHP2-IN-22
  • HY-P11058

    OVAp

    MHC Cancer
    OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 + T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .
    OVA(250-264)
  • HY-171745

    ATM/ATR Cancer
    ATR-IN-32 is an orally active ATR inhibitor. ATR-IN-32 potently inhibits the proliferation of MIA PaCa-2 cells. ATR-IN-32 exerts significant tumor growth inhibition in mice bearing LOVO and HT-29 xenografts. ATR-IN-32 can be used for the study of cancers mediated by ATR protein kinase, such as colorectal cancer, pancreatic cancer .
    ATR-IN-32
  • HY-177501

    CDK Apoptosis Cancer
    Otviciclib (Compound 86) is a CDK inhibitor. Otviciclib has potent anti-proliferative activity against solid tumor cells (such as HCT116, NCIH82 and DU145 cells) with no significant toxicity to normal cells, and effectively induces the G2/M phase cells arrest and apoptosis. Otviciclib has a broad-spectrum anticancer activity, such as colon, pancreatic and lung cancer .
    Otviciclib
  • HY-168022

    Aurora Kinase Cancer
    CAM2602 is an Aurora A-TPX2 interaction inhibitor that has a binding affinity of 19 nM to Aurora A. CAM2602 can inhibit the growth of pancreatic cancer cells. In solid tumor transplant models, CAM2602 can increase the proportion of PH3 positive cells while reducing the proportion of P-Thr288 Aurora A positive cells, thereby inhibiting tumor growth .
    CAM2602
  • HY-146738

    Akt Cancer
    GSD-11 is a potent and selective anti-austerity agent. GSD-11 inhibits the cell migration and colony formation of PANC-1 cells. GSD-11 inhibits the Akt/mTOR signaling pathway. GSD-11 has the potential for the research of pancreatic cancer[1].
    GSD-11
  • HY-177345

    Sigma Receptor Apoptosis Caspase Cancer
    SV119 is a selective sigma-2 (σ₂) receptor ligand (Ki ≈ 5-10 nM). SV119 induces apoptosis in various human cancer cell lines by activating caspase-3 and promoting mitochondrial depolarization. SV119 can enhance the effects of chemotherapeutic agents such as Paclitaxel (HY-B0015), increasing their cytotoxicity against tumor cells. SV119 significantly inhibits tumor growth in mouse xenograft models, both alone and in combination. SV119 is useful in the research of cancers such as breast, prostate, and pancreatic cancer .
    SV119
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant Antibody

    EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-16214
    FX-11
    Maximum Cited Publications
    27 Publications Verification

    LDHA Inhibitor FX11

    Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) Cancer
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
    FX-11
  • HY-P10944

    NNS309

    FAP Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-129389
    Benzyl-α-GalNAc
    5 Publications Verification

    Glycosyltransferase Cancer
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .
    Benzyl-α-GalNAc
  • HY-106777
    Cyclopentenylcytosine
    1 Publications Verification

    CPEC; NSC 375575

    DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Necroptosis Influenza Virus HSV Infection Cancer
    Cyclopentenylcytosine (CPEC), a carbocyclic nucleoside analog of cytosine, is a potent inhibitor of CTP synthetase and causes depletion of CTP and dCTP pools. Cyclopentenylcytosine shows broad-spectrum (both DNA and RNA viruses) antiviral activity. Cyclopentenyl cytosine increases Gemcitabine (HY-17026) radiosensitisation in human pancreatic cancer cells. Cyclopentenylcytosine shows effective antiviral activity in the Ad5/NZW rabbit ocular replication model and shows anti-tumor activity in various tumor xenografts model. Cyclopentenylcytosine can be used for the study of infection and cancer .
    Cyclopentenylcytosine
  • HY-P99379

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-144310

    Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor (IC50=3.6 nM). DX3-213B impairs ATP generation (IC50=11 nM), and blocks MIA PaCa-2 cell growth (GI50=11 nM). DX3-213B is used for the research of the pancreatic cancer .
    DX3-213B
  • HY-P990237

    CD28 Inflammation/Immunology Cancer
    Anti-Mouse ICOS Antibody (7E.17G9) is an anti-mouse ICOS IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
    Anti-Mouse ICOS Antibody (7E.17G9)
  • HY-144338

    Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis Cancer
    PARP1/BRD4-IN-1 is a potent and high selective PARP1/BRD4 inhibitor (IC50s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .
    PARP1/BRD4-IN-1
  • HY-P990254

    CXCR Inflammation/Immunology Cancer
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
  • HY-N7287

    Others Others
    (+)-Matairesinol is a lignan. (+)-Matairesinol has no cytotoxic activity for human pancreatic PANC-1 cancer cells .
    (+)-Matairesinol
  • HY-156328

    Apoptosis Cancer
    NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .
    NSC 48160
  • HY-14570

    Apoptosis Cancer
    Triphen diol is a phenol diol derivative, which has excellent anticancer activity against pancreatic cancer and cholangiocarcinoma, and can induce pancreatic cell apoptosis through two mechanisms, caspase-mediated and caspase-independent .
    Triphen diol
  • HY-164483

    Akt Trk Receptor Cancer
    HS-345 is a TrkA/Ak inhibitor with significant anti-pancreatic cancer effects. HS-345 inhibits the growth and proliferation of pancreatic cancer cells by targeting the TrkA/Akt signaling pathway, while also inducing apoptosis. Additionally, HS-345 suppresses blood vessel formation by decreasing the expression of HIF-1α and VEGF. HS-345 holds promise for research in pancreatic cancer .
    HS-345
  • HY-159511

    Hedgehog Cancer
    Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .
    Hedgehog IN-7
  • HY-123056

    Autophagy Apoptosis Cancer
    EAD1 is a potent autophagy inhibitor with antiproliferative activity in lung and pancreatic cancer cells. EAD1 also induces apoptosis .
    EAD1
  • HY-N1427
    Glycodeoxycholate Sodium
    3 Publications Verification

    Sodium glycyldeoxycholate

    Endogenous Metabolite Metabolic Disease
    Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .
    Glycodeoxycholate Sodium
  • HY-N8034

    Apoptosis Autophagy Cancer
    Glychionide A is a flavonoside that can be found in the roots of Glychirriza glabra. Glychionide A promotes apoptosis and autophagy of PANC-1 pancreatic cancer cells. Glychionide A can be used for the research of cancer .
    Glychionide A
  • HY-175202

    Discoidin Domain Receptor Apoptosis Caspase Interleukin Related PERK Cancer
    CIDD-8633 is a potent DDR2 inhibitor with an IC50 of 6.105 μM. CIDD-8633 inhibits cell migration and halts the cell cycle and induces apoptosis, significantly suppressing pancreatic ductal adenocarcinoma (PDAC) tumor growth. CIDD-8633 can be used for the study of pancreatic cancer such as PDAC .
    CIDD-8633
  • HY-100885A

    (S)-NUC-1031; Fosgemcitabine palabenamide

    Others Cancer
    (S)-Acelarin ((S)-NUC-1031) is an anti-cancer agent. (S)-Acelarin inhibits the growth of various cancer cells. (S)-Acelarin can be used for the study of solid tumors (e.g., pancreatic cancer, BTC, ovarian cancer) and hematological malignancies .
    (S)-Acelarin
  • HY-W854385

    SLeA

    Biochemical Assay Reagents Cancer
    Sialyl Lewis A (SLeA) is a carbohydrate-type antigen that can serve as a tumor marker, with upregulation observed in various tumor cells such as cervical cancer, human pancreatic cancer, and colon cancer cells. Sialyl Lewis A is involved in the migration and adhesion of tumor cells. Additionally, elevated expression of Sialyl Lewis A may also lead to pregnancy abnormalities .
    Sialyl Lewis A
  • HY-P991237

    HMBD-001

    EGFR Cancer
    Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
    Nezutatug
  • HY-137432A
    Avotaciclib trihydrochloride
    2 Publications Verification

    BEY1107 trihydrochloride

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) trihydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib trihydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib trihydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib trihydrochloride
  • HY-137432B
    Avotaciclib hydrochloride
    2 Publications Verification

    BEY1107 hydrochloride

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib hydrochloride
  • HY-137432
    Avotaciclib
    2 Publications Verification

    BEY1107

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib
  • HY-160061

    Biochemical Assay Reagents Cancer
    P12FR2 aptamer sodium is a 2'-fluoropyrimidine-modified RNA aptamer targeting human PAUF with an estimated apparent KD of 77 nM. P12FR2 aptamer sodium inhibits PAUF-induced migration of PANC-1 (human pancreatic cancer cells) in wound healing assays and suppresses tumor growth in a mouse CFPAC-1 pancreatic cancer model .
    P12FR2 aptamer sodium
  • HY-P99049

    APX005M; APX005M; EPI-0050

    TNF Receptor Inflammation/Immunology
    Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
    Sotigalimab
  • HY-W009065

    Others Cardiovascular Disease Cancer
    Hydroquinidine hydrochloride is a potent ion channel blocker, which exhibits strong anti-cancer activity on colon, pancreatic, and hepatocellular cancer cells. Hydroquinidine hydrochloride prolongs the QT interval and has antiarrhythmic efficacy .
    Hydroquinidine hydrochloride
  • HY-110182
    SP-141
    3 Publications Verification

    MDM-2/p53 Cancer
    SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .
    SP-141
  • HY-B0997

    Dihydroquinidine; (+)-Hydroquinidine; Hydroconquinine

    Others Cardiovascular Disease Cancer
    Hydroquinidine (Dihydroquinidine) is a potent ion channel blocker, which exhibits strong anti-cancer activity on colon, pancreatic, and hepatocellular cancer cells. Hydroquinidine prolongs the QT interval and has antiarrhythmic efficacy .
    Hydroquinidine
  • HY-178520

    Cadherin Cancer
    BAS00132635 (Compound AS9) is an E-cadherin inhibitor. BAS00132635 can block trans-interactions of E-cadherin molecules in junctional complexes and reduce the number of cancer cells exhibiting invadopodia. BAS00132635 can be used for the research of cancer, such as Pancreatic cancer .
    BAS00132635
  • HY-137432D

    BEY1107 sulfate

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib sulfate
  • HY-147526

    Apoptosis Cancer
    RM-581, an aminosteroid derivative, is an endoplasmic reticulum stress (ERS) inducer. RM-581 induces cancer cells apoptosis. RM-581 can be used for the study of pancreatic, prostate and breast cancers .
    RM-581
  • HY-164451

    γ-secretase Notch Cancer
    GSI-18 is a γ-secretase inhibitor with anticancer activity. GSI-18 inhibits the attachment-free growth of pancreatic cancer cells by inhibiting Notch signaling .
    GSI-18

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: